LymPro as an LDT "If successful, LymPro can begin

New Post Public Reply Private Reply Replies (0) Message Board
jpetroinc
LymPro as an LDT

"If successful, LymPro can begin generating revenue as a laboratory developed test (LDT) within 18 months of study initiation through commercial sales and through sales to companies performing Alzheimer's disease clinical research." GC 12/14/2012

"We are pleased with the reproducibility we have seen with the assay at BD," commented Paul Jorgensen, Head of Diagnostics Product Development at Amarantus. "We evaluated various conditions for assay performance and were able to clearly demonstrate suitable analytical performance that will underpin the validity of the ability of LymPro to differentiate Alzheimer's from non-Alzheimer's using both univariate and multivariate models. We are pleased to be sharing the data, along with a scientific and clinical data summary to support the cell cycle dysregulation hypothesis in Alzheimer's disease." PJ 07/14/2104

AMBS expects to formally present LymPro's sensitivity and specificity data at the C4CT UN Summit in NYC, this Thur., July 31st, 2014.

AMBS expects to beging LDT sales and generating revenue starting 4Q14

AMBS expects to provide formal revenue guidance in 3Q14

AMBS expects to announce LymPro JV Partner by end of summer, 2014

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 1

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 4

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 6

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 9

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 2

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 5

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 6

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading

Top 5 Most Recently Viewed Articles

Cingulate Inc. Shows Progress with Q2 2025 Financial Results

Updated Category News Views 142

Cingulate Inc. Announced Financial Highlights for Q2 2025 Cingulate Inc. (NASDAQ: CING), a prominent biopharmaceutical company focused on innovative ADHD treatments, recently disclosed its financial results for the second quarter of 2025, alongside significant advancements. Central to the company’s activities was the submission of the New Drug Application (NDA) for its...

Continue Reading
Discover How Your Investment in Carvana Could Have Grown

Updated Category News Views 127

Investment Growth Over Five Years Investing wisely can create remarkable returns over time. A case in point is Carvana Co (NASDAQ: CVNA), which has significantly outperformed expectations in recent years. Over the past five years, Carvana has shown an impressive annualized return of 18.46%, surpassing the market by 4.39% each year. Presently, Carvana's market...

Continue Reading
Deko Cocktails Triumphs with Best New RTD Award Success

Updated Category News Views 92

Deko Cocktails Achieves WSWA Best RTD Award Deko Cocktails, a newly launched line of expertly crafted ready-to-serve cocktails, recently secured a prestigious accolade in the beverage alcohol industry. The company was honored with the Best RTD (Ready to Drink) Product of the Year at the Wine & Spirit Wholesalers of America (WSWA) Brand Battle. This annual competition...

Continue Reading
Bouygues SA Shares and Voting Rights Update for January 2025

Updated Category News Views 205

Key Insights on Bouygues SA's Monthly Share and Voting Rights Bouygues SA regularly updates its shareholders about essential metrics, including the total number of shares and the voting rights attached to them. Understanding these details is vital for investors and stakeholders who wish to stay informed of the company's standing in the market. Transparency in Shareholder...

Continue Reading
Challenges Faced by Oncternal Therapeutics and Stock Update

Updated Category News Views 94

Oncternal Therapeutics Inc. (ONCT) was in dire straits back then, hitting a notable low of $1.31 amidst a turbulent market that left investors biting their nails. This stock plunge represented a hefty drop of -76.33%, rattling traders who were already on edge over the biopharmaceutical company’s struggle to bring innovative cancer therapies to market. The company's...

Continue Reading